NasdaqGS - Nasdaq Real Time Price USD

PTC Therapeutics, Inc. (PTCT)

Compare
37.56 -0.10 (-0.27%)
At close: September 27 at 4:00 PM EDT
37.56 0.00 (0.00%)
After hours: September 27 at 4:45 PM EDT
Loading Chart for PTCT
DELL
  • Previous Close 37.66
  • Open 38.06
  • Bid 37.52 x 200
  • Ask 37.62 x 200
  • Day's Range 37.23 - 38.06
  • 52 Week Range 17.53 - 40.69
  • Volume 775,077
  • Avg. Volume 572,793
  • Market Cap (intraday) 2.895B
  • Beta (5Y Monthly) 0.65
  • PE Ratio (TTM) --
  • EPS (TTM) -6.30
  • Earnings Date Oct 24, 2024 - Oct 28, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 38.85

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

www.ptcbio.com

988

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PTCT

View More

Performance Overview: PTCT

Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PTCT
36.28%
S&P 500
20.30%

1-Year Return

PTCT
66.19%
S&P 500
34.27%

3-Year Return

PTCT
4.40%
S&P 500
28.79%

5-Year Return

PTCT
4.68%
S&P 500
92.71%

Compare To: PTCT

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PTCT

View More

Valuation Measures

Annual
As of 9/27/2024
  • Market Cap

    2.90B

  • Enterprise Value

    2.20B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.17

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    2.43

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -53.25%

  • Return on Assets (ttm)

    -7.39%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    900.45M

  • Net Income Avi to Common (ttm)

    -479.52M

  • Diluted EPS (ttm)

    -6.30

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.09B

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -84.33M

Research Analysis: PTCT

View More

Company Insights: PTCT

Research Reports: PTCT

View More

People Also Watch